Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

NEXT STORY
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock
PREV STORY
Exosomes Market Research Report by Product, by Treatment, by Workflow, by End-User, by Application, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product Launch

BUFFALO, N.Y., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical ...

author_avatar
NASDAQ Market News

Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update

MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a ...

author_avatar
NASDAQ Market News

CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News